In conclusion, we identified a CAF subset marked by Meflin expression and found its prevalence to be associated with a favorable response to ICB therapy in patients with NSCLC and syngeneic tumor mouse models. The gene discussed is ISLR; the disease is non-small cell lung carcinoma.